We are a team of experienced scientists and innovators, passionate about helping to solve significant human health challenges through biomedical research. From preclinical proof-of concept to IND-enabling studies, Virscio’s goal is to bring clarity and confidence to R&D investment decision making and improve the odds of clinical translation. We fully support critical development stages, spanning preclinical strategy, protocol design, in-life study execution, sample processing, data analysis, study reporting and defining regulatory path, with a focus on in vivo primate efficacy and safety, pharmacokinetics, pharmacodynamics and therapeutic delivery. Our capabilities are enabled by broad experience, including:
- 30+ years of translational R&D experience
- 80+ team with exceptional retention, many having decades of experience
- 10+ MD and/or PhD Study Directors
- 500+ industry preclinical study / program engagements
- 30+ models validated and applied to therapeutic program development
- Significant engagement with large pharma, venture-backed, and academic clients from around the world
Virscio is seeking experienced, creative, and highly motivated individuals with the ability to lead and contribute to multidisciplinary R&D initiatives supported by leading biotechnology and pharmaceutical companies.
9 articles with Virscio
Virscio Publishes Data Validating Non-Human Primate Model for Testing Chronic Retinal Neovascularization and Vascular Leakage Drug Candidates
Virscio, a translational research company providing definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced publication of data that validate a nonhuman primate (NHP) model for testing drug candidates targeting retinal ischemic and neovascular diseases
RxGen to Present Alzheimer’s Disease APP/Abeta Cellular and Animal Models at the Society for Neuroscience’s 49th Annual Meeting
One of the primary challenges in drug development is the inability of preclinical models to reliably predict clinical outcomes.
RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease
RxGen, Inc. and Santaris Pharma A/S Use LNA-antimiR Technology to Antagonize the Liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol
RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO